LRRK2 and prostate adenocarcinoma: By stratifying for organ sites, a similar result was observed for prostate adenocarcinoma (LRRK2 altered: 6/16 deceased, median OS months: 120, vs. LRRK non-altered: 127/649 deceased, median OS: 115.13 months; p = 0.037); interestingly, an opposite, statistically significant trend was noted for endometrial carcinoma (LRRK2 altered: 6/85 deceased, median OS: NA, vs. LRRK non-altered: 110/479 deceased, median OS: 110.10 months; p = 0.0001481; Figure 5).